Keryx Biopharmaceuticals, Inc. (KERX) Rating Reiterated by Cowen and Company
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX)‘s stock had its “market perform” rating reiterated by research analysts at Cowen and Company in a report released on Tuesday.
A number of other brokerages have also commented on KERX. Zacks Investment Research raised Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 price objective for the company in a report on Wednesday, July 12th. BidaskClub lowered Keryx Biopharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Maxim Group reissued a “buy” rating and set a $9.00 price objective on shares of Keryx Biopharmaceuticals in a report on Thursday, July 20th. Finally, ValuEngine lowered Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, six have given a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $8.27.
Shares of Keryx Biopharmaceuticals (KERX) traded up 1.10% during midday trading on Tuesday, hitting $7.37. The company’s stock had a trading volume of 462,395 shares. The company’s market cap is $799.39 million. Keryx Biopharmaceuticals has a 1-year low of $4.03 and a 1-year high of $8.38. The company has a 50-day moving average price of $7.03 and a 200 day moving average price of $6.06.
Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by $0.03. The company had revenue of $11.82 million for the quarter, compared to the consensus estimate of $10.19 million. Keryx Biopharmaceuticals had a negative return on equity of 1,122.28% and a negative net margin of 387.12%. The business’s revenue for the quarter was up 73.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.39) earnings per share. On average, equities research analysts predict that Keryx Biopharmaceuticals will post ($0.69) EPS for the current year.
COPYRIGHT VIOLATION WARNING: This article was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.americanbankingnews.com/2017/07/25/keryx-biopharmaceuticals-inc-kerx-rating-reiterated-by-cowen-and-company-2.html.
Institutional investors have recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. acquired a new position in Keryx Biopharmaceuticals during the first quarter valued at about $616,000. Credit Suisse AG raised its position in Keryx Biopharmaceuticals by 113.2% in the first quarter. Credit Suisse AG now owns 166,497 shares of the biopharmaceutical company’s stock valued at $1,025,000 after buying an additional 88,411 shares in the last quarter. Clough Capital Partners L P raised its position in Keryx Biopharmaceuticals by 35.8% in the first quarter. Clough Capital Partners L P now owns 106,700 shares of the biopharmaceutical company’s stock valued at $657,000 after buying an additional 28,100 shares in the last quarter. Jane Street Group LLC acquired a new position in Keryx Biopharmaceuticals during the first quarter valued at about $141,000. Finally, Endurant Capital Management LP acquired a new position in Keryx Biopharmaceuticals during the first quarter valued at about $875,000. 62.26% of the stock is owned by institutional investors.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.